Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

Annals of Oncology

Volumn 12, Issue 7, 2001, Pages 987-990

  Bertolini, F ^a   Mingrone, W ^a   Alietti, A ^a   Ferrucci, P F ^a   Cocorocchio, E ^a   Peccatori, F ^a   Cineri, S ^a   Mancuso, P ^a   Corsini, C ^a   Burlini, A ^a   Zucca, E ^a   Martinelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Angiogenesis; Histiocytosis; Myelodysplastic syndromes; Myeloma; Thalidomide

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; BONE MARROW; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONSTIPATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; ERYTHROCYTE TRANSFUSION; FEMALE; FLOW CYTOMETRY; HISTIOCYTOSIS; HUMAN; HYPOTENSION; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH DISEASE; THROMBOCYTE TRANSFUSION; VERTIGO;

EID: 0034903286     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011141009812     Document Type: Article

References (16)

1. Current role of thalidomide in cancer treatment
2. Thalidomide is an inhibitor of angiogenesis
3. Bone marrow angiogenesis and progression in multiple myeloma
4. Antitumor activity of thalidomide in refractory multiple myeloma
5. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug
6. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
7. Angiogenesis in myelodysplastic syndromes
8. Pharmacology of thalidomide
9. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
10. Human myeloid and lymphoid malignancies in the NOD/SCID mouse model: Frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with VEGF production
11. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
12. Report of an international working group to standardize response criteria for myelodysplastic syndromes
13. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?
14. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
15. The thin red line: Angiogenesis in normal and malignant hematopoiesis
16. Serum levels of the angiogenic cytokines b-FGF, VEGF and HGF in multiple myeloma